期刊文献+

福辛普利对糖尿病大鼠肾脏损伤的保护作用 被引量:2

Protective effect of fosinopril on renal damage in rats with diabetics mellitus
原文传递
导出
摘要 目的探讨福辛普利对糖尿病大鼠肾脏损伤的保护机制。方法制备大鼠糖尿病模型并分别给予不同剂量福辛普利灌胃。12周后检测血糖、血清肌酐、肾重指数,观察肾小球体积、肾小球基底膜变化,测定肾小球平均截面积(MGA)和肾小球平均体积(MGV)。结果 DM组及不同剂量福辛普利组间血糖、血清肌酐均无统计学差异;与DM组相比,5mg·kg^(-1)·d^(-1)组肾重指数降低(P<0.05),10mg·kg^(-1)·d^(-1)组肾重指数明显降低(P<0.01),各福辛普利组MGA和MGV均缩小(P均<0.01)。绪论早期应用福辛普利在一定程度上可减轻糖尿病大鼠肾脏的损伤。 Objective To investigate the protective effects of fosinopril on the diabetic nephropathy in diabetic rats. Methods Diabetic model rats were established by intra-abdominal injection of streptozotocin. Fosinopril-treated rats were administered by gastric canal at different dose of fosinopril respectively. Affer 12 weeks, blood sugar and creatinine, kidney weight index were examined in all groups. Kidney paraffin section was prepared. Glomerular volume, basement membrane changes, mean glornerular section area (MGA) and volume (MGV) were determined. Results The blood suger and creatinine did not change obviously. Kidney weight index had no significant differences in 2.5mg·kg^-1·d^-1 group,but had significant differences in 5mg·kg^-1·d^-1 group(P〈0.05)and 10mgmg·kg^-1·d^-1 group(P 〈0. 01). MGA and MGV in fosinopril-treated groups had significant diminutions as compared with DM group(P〈0. 01). Conclusions Fosinopril administered in early stage could attenuate the kidney damage in diabetic rats.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2009年第1期66-67,74,共3页 Chinese Journal of Diabetes
关键词 福辛普利 糖尿病肾病 血管紧张素转换酶抑制剂 Fosinopril Diabetic nephropathy Angiotensin converting enzyme inhibitors
  • 相关文献

参考文献4

二级参考文献16

  • 1Boder W,Nobel NA. Evidence that TGFβ1 should be a therapeutic taget in diabetic nephropathy[J]. Kidney Int,1998,54:1130-46.
  • 2Bertoluci MC. Transforming growth factor β in the development of rat diabetic nephropathy. A 10-month study with insulin-treated rats[J]. Nephron,1996,10(9):1891-9.
  • 3Yang CW. Advanced glycoslation end products upregulate gene expression found in diabetic glomerular disease[J]. Proc Natl Acad Sci,1994,91:9346-440.
  • 4Kim YS, Kim BC, Song CY et al. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta[J]. J Lab Clin Med, 2001,138(1): 59-68.
  • 5Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin Ⅱ[J]. J Clin Invest,1992,90(2): 456-61.
  • 6Gilbert RE, Cox A, Wu LL et al. Expression of transforming growth factor β1 and type Ⅳ collagen in the renal tubulointestitium in experimental diabetes:Effect of ACE inhibition[J]. Diabetes, 1998,47(3):414-22.
  • 7Kelly DJ. Effects of endothelin or angiotensin Ⅱ receptor blockade on diabetes in the transgenic (mRen-2)27 rat[J]. Kidney Int, 2000,57:1882-94.
  • 8Agarwal R,Siva S,Dunn SR et al. Add-on angiotensin Ⅱ receptor blocker lowers the urinary transforming growth factor beta levels[J]. Am J Kidey Dis, 2002,39(3):486-92.
  • 9Leehey DJ, Singh AK, Alavi, et al. Role of angiotensin Ⅱ in diabetic nephropaty [J]. Kidney Int, 2000,77 : S93-S98.
  • 10Singh R, Alavi N, Singh AK, et al. Role of angiotensin Ⅱ in glucose-induced inhibition of mesangial matrix degration [J].Diabetes, 1999,48(10) :2066-2073.

共引文献13

同被引文献8

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部